CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors), ERs antagonists(Estrogen receptors antagonists)

+ [1]

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal Diseases

Active Indication

Hormone receptor positive HER2 negative breast cancer

Inactive Indication-

Originator Organization

Novartis Pharma AG

Active Organization

Sarah Cannon Research Institute LLC

Texas Oncology PA

Florida Cancer Specialists & Research Institute LLC

+ [4]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (04 May 2017),

Hormone receptor positive HER2 negative breast cancer

RegulationBreakthrough Therapy (US)

Structure

Molecular FormulaC17H11N5

InChIKeyHPJKCIUCZWXJDR-UHFFFAOYSA-N

CAS Registry112809-51-5

View All Structures (2)

Clinical Trials associated with Letrozole/Ribociclib Succinate

NCT03283384 / Active, not recruitingPhase 2IIT

Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.

The aim of this prospective, randomized, multicenter, open-label, phase II study is to test if chemotherapy can be replaced by the combination of ribociclib plus letrozole as a neo-adjuvant therapy for patients with non-metastatic primary luminal breast cancer.

Start Date15 Jun 2019

Sponsor / Collaborator

Novartis AG

[+1]

100 Clinical Results associated with Letrozole/Ribociclib Succinate

100 Translational Medicine associated with Letrozole/Ribociclib Succinate

100 Patents (Medical) associated with Letrozole/Ribociclib Succinate

Literatures (Medical) associated with Letrozole/Ribociclib Succinate

31 Dec 2024·Future Science OA

Gastric metastasis and peritoneal carcinosis revealing primary breast cancer: an unusual presentation

Article

Author: Zaimi, Yosra ; Mouelhi, Leila ; Safta, Amine Ben ; Ayadi, Shema ; Aloui, Raoudha ; Samaali, Imen ; Hammami, Mehdi ; Blel, Ahlem ; Monastiri, Souhir ; Kammoun, Mehdi

Breast cancer is the most frequent cancer among women. Gastrointestinal tract metastases are uncommon and might be misidentified as primary carcinoma. A noteworthy case-study involved 53-year-old-woman complaining from epigastric pain, ascites and overall health decline. Initial investigations were inconclusive, prompting laparoscopic peritoneal biopsies which revealed independent cell proliferation. Subsequently, a second look upper digestive endoscopy showed multiple gastric ulcerations suggestive of gastric carcinoma. Histologic examination confirmed independent cell proliferation with estrogen receptors expression, a characteristic feature of breast carcinoma. Further investigations led to bilateral invasive lobular breast carcinoma diagnosis. Epirubicin cycophosphamide was prescribed after progression under letrozole ribocilib therapy. This case aims to raise awareness among clinicians about the importance of ruling out breast cancer in patients with peritoneal carcinosis and paying attention to digestive symptoms in breast cancer patients with careful gastric endoscopic examination to avoid misdiagnosis.

01 Sep 2023·Journal of Oncology Pharmacy Practice

Toxic hepatitis in metastatic breast cancer patient using ribociclib and denosumab

Article

Author: Uçar, Gökhan ; Bayram, Doğan ; Aktürk Esen, Selin ; Köş, Fahriye Tuğba

Introduction Hepatotoxicity is observed due to cyclin-dependent kinase (CDK4/6) inhibitors used to treat hormone receptor-positive metastatic breast cancer. However, it should not be ignored that denosumab may be hepatotoxic, although it is rare. Case Report A 73-year-old female patient with breast cancer with axillary lymph node, adrenal gland and bone metastases was started on ribociclib letrozole and denosumab treatment. Ribociclib treatment was discontinued due to grade 4 hepatotoxicity during treatment, but liver function tests did not decrease. After discontinuation of denosumab treatment, alanine aminotransferase and aspartate aminotransferase values regressed to baseline values. Management and Outcome Despite the discontinuation of ribociclib treatment, other causes of liver toxicity were investigated due to persistence of hepatic transaminases and elevation. Autoimmune hepatitis markers were negative. Hepatobiliary USG did not reveal any pathological findings except hepatosteatosis. Liver biopsy was performed to determine the etiology. Pathology result was compatible with acute hepatocellular damage (in favor of toxic hepatitis). A decrease in liver values was detected after discontinuation of denosumab treatment. Discussion Although cases with improvement in liver enzymes have been reported after discontinuation of ribociclib, no improvement in hepatotoxicity was observed in our case. Since the liver biopsy was toxic hepatitis, it was thought that other drugs used by the patient might cause this toxicity, and a significant decrease was observed in liver values after discontinuation of denosumab. Denosumab-induced liver toxicity is very rare, and there are only a limited number of cases in the literature.

100 Deals associated with Letrozole/Ribociclib Succinate

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XE	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hormone receptor positive HER2 negative breast cancer	US	Novartis Pharmaceuticals Corp.	04 May 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hormone receptor positive HER2 negative breast cancer	Phase 3	US	Sarah Cannon Research Institute LLC	30 May 2017
Hormone receptor positive HER2 negative breast cancer	Phase 3	US	Texas Oncology PA	30 May 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


OncoDynamics project (EHA2019)	Not Applicable	Metastatic breast cancer	7	Ribociclib plus letrozole	qnfrbyjwcs(ywojkvsqme) = 4 patients (57,1%) had a sustained rise of the mean corpuscular volume (MCV > 97 fL) noezyvedda (jrcnkraznp )	-	16 May 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Letrozole/Ribociclib Succinate

Overview

Basic Info

Structure

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation